GP29 | CAS#1415050-59-7 | kinase inhibitor

MedKoo Cat#: 562683 | Name: GP29

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GP29 is a Type II kinase inhibitor of the IRE1α endoribonuclease. It acts by targeting the ATP-binding pocket of IRE1α.

Chemical Structure

GP29

CAS#1415050-59-7

Theoretical Analysis

MedKoo Cat#: 562683

Name: GP29

CAS#: 1415050-59-7

Chemical Formula: C33H28F3N5O3

Exact Mass: 599.2144

Molecular Weight: 599.61

Elemental Analysis: C, 66.10; H, 4.71; F, 9.51; N, 11.68; O, 8.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

GP29; GP-29; GP 29;

IUPAC/Chemical Name

N-[3-[2-[[4-[2-(Acetylamino)ethoxy]phenyl]amino]-6-quinazolinyl]-4-methylphenyl]-3-(trifluoromethyl)-benzamide

InChi Key

ATHXRUPPJMCHKW-UHFFFAOYSA-N

InChi Code

InChI=1S/C33H28F3N5O3/c1-20-6-8-27(39-31(43)23-4-3-5-25(17-23)33(34,35)36)18-29(20)22-7-13-30-24(16-22)19-38-32(41-30)40-26-9-11-28(12-10-26)44-15-14-37-21(2)42/h3-13,16-19H,14-15H2,1-2H3,(H,37,42)(H,39,43)(H,38,40,41)

SMILES Code

O=C(NC1=CC=C(C)C(C2=CC3=CN=C(NC4=CC=C(OCCNC(C)=O)C=C4)N=C3C=C2)=C1)C5=CC=CC(C(F)(F)F)=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 599.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mehla J, Dedrick RM, Caufield JH, Wagemans J, Sakhawalkar N, Johnson A, Hatfull GF, Uetz P. Virus-host protein-protein interactions of mycobacteriophage Giles. Sci Rep. 2017 Nov 28;7(1):16514. doi: 10.1038/s41598-017-16303-7. PubMed PMID: 29184079; PubMed Central PMCID: PMC5705681. 2: Hu B, Margolin W, Molineux IJ, Liu J. Structural remodeling of bacteriophage T4 and host membranes during infection initiation. Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4919-28. doi: 10.1073/pnas.1501064112. Epub 2015 Aug 17. PubMed PMID: 26283379; PubMed Central PMCID: PMC4568249. 3: Paul J, Naskar K, Chowdhury S, Alam MN, Chakraborti T, De T. TLR4-mediated activation of MyD88 signaling induces protective immune response and IL-10 down-regulation in Leishmania donovani infection. Indian J Biochem Biophys. 2014 Dec;51(6):531-41. PubMed PMID: 25823227. 4: Paul J, Naskar K, Chowdhury S, Chakraborti T, De T. TLR mediated GSK3β activation suppresses CREB mediated IL-10 production to induce a protective immune response against murine visceral leishmaniasis. Biochimie. 2014 Dec;107 Pt B:235-46. doi: 10.1016/j.biochi.2014.09.004. Epub 2014 Sep 16. PubMed PMID: 25223889. 5: Peixeiro N, Keller J, Collinet B, Leulliot N, Campanacci V, Cortez D, Cambillau C, Nitta KR, Vincentelli R, Forterre P, Prangishvili D, Sezonov G, van Tilbeurgh H. Structure and function of AvtR, a novel transcriptional regulator from a hyperthermophilic archaeal lipothrixvirus. J Virol. 2013 Jan;87(1):124-36. doi: 10.1128/JVI.01306-12. Epub 2012 Oct 10. PubMed PMID: 23055559; PubMed Central PMCID: PMC3536394. 6: Zehr ES, Tabatabai LB, Bayles DO. Genomic and proteomic characterization of SuMu, a Mu-like bacteriophage infecting Haemophilus parasuis. BMC Genomics. 2012 Jul 23;13:331. PubMed PMID: 22823751; PubMed Central PMCID: PMC3447690. 7: Paul J, Karmakar S, De T. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis. Eur J Immunol. 2012 Aug;42(8):2087-99. doi: 10.1002/eji.201242428. PubMed PMID: 22622993. 8: Zehr ES, Tabatabai LB. Detection of a bacteriophage gene encoding a Mu-like portal protein in Haemophilus parasuis reference strains and field isolates by nested polymerase chain reaction. J Vet Diagn Invest. 2011 May;23(3):538-42. doi: 10.1177/1040638711404143. PubMed PMID: 21908286. 9: Henry M, Begley M, Neve H, Maher F, Ross RP, McAuliffe O, Coffey A, O'Mahony JM. Cloning and expression of a mureinolytic enzyme from the mycobacteriophage TM4. FEMS Microbiol Lett. 2010 Oct;311(2):126-32. doi: 10.1111/j.1574-6968.2010.02080.x. Epub 2010 Aug 19. PubMed PMID: 20727013. 10: Fil'chikov MV, Osmakov DI, Logovskaia LV, Sykilinda NN, Kadykov VA, Kurochkina LP, Mesianzhinov VV, Bernal RA, Miroshnikov KA. [Pseudomonas aeruginosa bacteriophage SN: 3D-reconstruction of the capsid and identification of surface proteins by electron microscopy]. Bioorg Khim. 2009 Nov-Dec;35(6):808-15. Russian. PubMed PMID: 20208580. 11: Kurochkina LP, Aksyuk AA, Sachkova MY, Sykilinda NN, Mesyanzhinov VV. Characterization of tail sheath protein of giant bacteriophage phiKZ Pseudomonas aeruginosa. Virology. 2009 Dec 20;395(2):312-7. doi: 10.1016/j.virol.2009.09.015. Epub 2009 Oct 12. PubMed PMID: 19822340. 12: Hewitson JP, Harcus YM, Curwen RS, Dowle AA, Atmadja AK, Ashton PD, Wilson A, Maizels RM. The secretome of the filarial parasite, Brugia malayi: proteomic profile of adult excretory-secretory products. Mol Biochem Parasitol. 2008 Jul;160(1):8-21. doi: 10.1016/j.molbiopara.2008.02.007. Epub 2008 Feb 16. PubMed PMID: 18439691. 13: Ishimoto M, Yamada T, Kaga A. Insecticidal activity of an alpha-amylase inhibitor-like protein resembling a putative precursor of alpha-amylase inhibitor in the common bean, Phaseolus vulgaris L. Biochim Biophys Acta. 1999 Jun 15;1432(1):104-12. PubMed PMID: 10366733. 14: Rao UR, Nasarre C, Coleman SU, Horohov DW, Klei TR. Granulomatous inflammatory response to recombinant filarial proteins of Brugia species. Am J Trop Med Hyg. 1999 Feb;60(2):251-4. PubMed PMID: 10072145. 15: Chacón MR, Londoño P, Dougan G, Selkirk ME. Heterologous expression of the cuticular-glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of Salmonella typhimurium abrogates H-2 restriction of specific antibody responses. Parasite Immunol. 1996 Jun;18(6):307-16. PubMed PMID: 9229383. 16: Tang L, Smith VP, Gounaris K, Selkirk ME. Brugia pahangi: the cuticular glutathione peroxidase (gp29) protects heterologous membranes from lipid peroxidation. Exp Parasitol. 1996 Apr;82(3):329-32. PubMed PMID: 8631385. 17: Selkirk ME, Gregory WF, Jenkins RE, Maizels RM. Localization, turnover and conservation of gp15/400 in different stages of Brugia malayi. Parasitology. 1993 Nov;107 ( Pt 4):449-57. PubMed PMID: 8278224. 18: Cookson E, Tang L, Selkirk ME. Conservation of primary sequence of gp29, the major soluble cuticular glycoprotein, in three species of lymphatic filariae. Mol Biochem Parasitol. 1993 Mar;58(1):155-9. PubMed PMID: 8459826. 19: Zvelebil MJ, Tang L, Cookson E, Selkirk ME, Thornton JM. Molecular modelling and epitope prediction of gp29 from lymphatic filariae. Mol Biochem Parasitol. 1993 Mar;58(1):145-53. PubMed PMID: 7681545. 20: Wilhelm K, Rüger W. Deoxyuridylate-hydroxymethylase of bacteriophage SPO1. Virology. 1992 Aug;189(2):640-6. PubMed PMID: 1641983.